{
    "nct_id": "NCT05133531",
    "official_title": "A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy",
    "inclusion_criteria": "1. Diagnosis of PNH confirmed by high-sensitivity flow cytometry testing with PNH granulocytes or monocytes as described in the protocol\n2. Active disease, as defined by the presence of 1 or more PNH-related signs or symptoms as described in the protocol\n3. LDH level ≥2 × ULN at the screening visit\n4. Willing and able to comply with clinic/remote visits and study-related procedures, including completion of the full series of meningococcal vaccinations required per protocol\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Prior treatment with eculizumab within 3 months prior to screening, ravulizumab within 6 months prior to screening, or other complement inhibitors within 5 half-lives of the respective agent prior to screening\n2. Receipt of an organ transplant, history of bone marrow transplantation or other hematologic transplant\n3. Body weight <40 kilograms at screening visit\n4. Planned use of any complement inhibitor therapy other than study drugs during the treatment period\n5. Not meeting meningococcal vaccination requirements and, at a minimum documentation of quadrivalent meningococcal vaccination within 5 years prior to the screening visit and serotype B vaccine within 3 years prior to the screening visit as described in the protocol.\n6. Any contraindication for receiving Neisseria meningitidis vaccinations (serotypes ACWY and B).\n7. Unable to take antibiotics for meningococcal prophylaxis (if required by local ravulizumab [Cohort A] or eculizumab [Cohort B] prescribing information, where available, or national guidelines/local practice, or if necessary when administration of the first dose of the vaccination is less than 2 weeks prior to study treatment initiation)\n8. Any active, ongoing infection or a recent infection requiring ongoing systemic treatment with antibiotics, antivirals, or antifungals within 2 weeks of screening or during the screening period\n9. Documented history of active, uncontrolled, ongoing systemic autoimmune diseases\n\nNote: Other protocol-defined Inclusion/ Exclusion Criteria apply",
    "miscellaneous_criteria": "Key"
}